Capricor Therapeutics Inc Total Liabilities
Capricor Therapeutics Inc total liabilities. Based on the latest financial reports, Capricor Therapeutics Inc (CAPR) has total liabilities worth $47.58 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Capricor Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Capricor Therapeutics Inc (1999–2025)
Total liabilities of Capricor Therapeutics Inc from 1999 to 2025. This chart illustrates how Capricor Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Capricor Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Capricor Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Capricor Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
|
Brazil | R$1.79 Billion |
|
Luoyang Northglass Technology Co Ltd
SHE:002613
|
China | CN¥732.57 Million |
|
Shenyu Communication Technology Inc
SHE:300563
|
China | CN¥802.17 Million |
|
Beijing Sanlian Hope Shin-Gosen Technical Service Co Ltd
SHE:300384
|
China | CN¥541.65 Million |
|
Faeth Therapeutics, Inc.
NASDAQ:FTH
|
USA | $16.35 Million |
|
Chipsea Technologies Shenzhen Corp Ltd
SHG:688595
|
China | CN¥748.77 Million |
|
Farmacias Benavides S.A.B. de C.V.
MX:BEVIDESB
|
Mexico | MX$5.49 Billion |
|
Zevra Therapeutics Inc.
NASDAQ:ZVRA
|
USA | $136.95 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Capricor Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Capricor Therapeutics Inc's balance sheet.
Liquidity & Leverage Metrics
Capricor Therapeutics Inc Total Liabilities Ratios Explained
Capricor Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Capricor Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Capricor Therapeutics Inc (1999–2025)
The table below shows the annual total liabilities of Capricor Therapeutics Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.16 Million | +100.48% |
| 2024-12-31 | $25.02 Million | -30.76% |
| 2023-12-31 | $36.13 Million | -5.68% |
| 2022-12-31 | $38.31 Million | +284.54% |
| 2021-12-31 | $9.96 Million | +55.20% |
| 2020-12-31 | $6.42 Million | +50.18% |
| 2019-12-31 | $4.27 Million | -7.71% |
| 2018-12-31 | $4.63 Million | -8.23% |
| 2017-12-31 | $5.05 Million | -77.82% |
| 2016-12-31 | $22.75 Million | +33.03% |
| 2015-12-31 | $17.10 Million | -13.98% |
| 2014-12-31 | $19.88 Million | +227.38% |
| 2013-12-31 | $6.07 Million | +1047.61% |
| 2012-12-31 | $529.17K | -2.27% |
| 2011-12-31 | $541.45K | -49.35% |
| 2010-12-31 | $1.07 Million | +67.69% |
| 2009-12-31 | $637.55K | -52.13% |
| 2008-12-31 | $1.33 Million | -29.51% |
| 2007-12-31 | $1.89 Million | +1301.86% |
| 2006-12-31 | $134.78K | +73.00% |
| 2005-12-31 | $77.91K | +31.16% |
| 2004-12-31 | $59.40K | +42.22% |
| 2003-12-31 | $41.77K | +70.09% |
| 2002-12-31 | $24.55K | +167.33% |
| 2001-12-31 | $9.19K | +920.56% |
| 2000-12-31 | $900.00 | 0.00% |
| 1999-12-31 | $900.00 | -- |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more